Financial results
Awaiting price reaction for this filing.
Eris Lifesciences reported its audited FY25 results with consolidated revenue from operations rising about 44% YoY to Rs 2,893.64 Crore (vs Rs 2,009.15 Crore in FY24), driven by recent acquisitions of the Biocon nephrology/dermatology and branded formulations businesses. Standalone revenue grew a more modest 14% to Rs 1,697.75 Crore. However, standalone net profit collapsed roughly 74% YoY to Rs 77.39 Crore (from Rs 299.72 Crore), hit by sharply higher finance costs (Rs 220 Cr vs Rs 57 Cr), heavier depreciation from acquisitions, and the end of the Section 80IE tax deduction. Consolidated PBT grew about 13% to Rs 488.87 Crore. Operating margin compressed from 25.98% to 20.04% on a standalone basis, and the company also sold subsidiary investments to Eris Therapeutics for Rs 872.19 Crore. Cash flow from operations was strong at Rs 701.87 Crore. The board reappointed cost auditors and appointed a new secretarial auditor for FY26-FY30.
Mixed for shareholders — top-line growth is healthy on a consolidated basis, but standalone profits have taken a steep hit from acquisition costs, higher borrowings, and the loss of a tax holiday, which may pressure the stock in the near term despite strong operating cash flows.